MedWatch

Novo Nordisk prepares for label expansion of prize asset

Novo Nordisk's GLP-1 analog semaglutide is already approved as treatment of diabetes and being tested against obesity and fatty liver disease. Now, the Danish drug group plans studies in chronic kidney disease and diabetic eye disease to further expand the molecule's label.

Foto: Ritzau Scanpix/Jacob Ehrbahn

Diabetes, obesity, fatty liver.

Danish Novo Nordisk sees several indication opportunities for the prize asset, semaglutide, and CSO Mads Krogsgaard Thomsen wants to further expand the molecule's label.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier